Cara Therapeutics | CARA - Sales Revenues


Cara Therapeutics reported $2.57M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Chugai Pharma JPY 341.6B 19.85B Jun/2026
Cipla INR 71.19B 5.78B Jun/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
RedHill Biopharma USD 1.29M 722K Jun/2024
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024